Triumvira Immunologics Inc.

AUSTIN, TX · Biotech · Private

TAC (proprietary immunotherapy) technology platform to enhance immune response against difficult-to-treat tumors

Claim this profile

Follows are private to you and power your alerts

Updated · triumvira.com

Sector
Biotech
Headquarters
AUSTIN, TX
Latest Form D
$16.2M, May 2021
Total capital
$16.2M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$16.2M
1 Form D · last May 2021
66 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

2021FEDERAL ↑EQUITY ↓Cumulative $16.2M1st Form D$16.2M
2021FEDERAL ↑EQUITY ↓Cumulative $16.2M1st Form D$16.2M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$16.2M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • BRIAN M. BLOOMDirectorNamed in SEC Form D filings
  • CYNTHIA M. COLLINS, MBADirectorNamed in SEC Form D filings
  • DANIEL C. JANSEDirectorNamed in SEC Form D filings
  • ELIZABETH C. WILLIAMSDirectorNamed in SEC Form D filings
  • JON C. IRVINExecutive OfficerNamed in SEC Form D filings
  • JURGEN M. ECKHARDTDirectorNamed in SEC Form D filings
Show all 12 people
  • LEE M. COOPERDirectorNamed in SEC Form D filings
  • PAUL LAMMERS, MD, MScExecutive Officer, DirectorNamed in SEC Form D filings
  • SCOTT C. SMITHDirectorNamed in SEC Form D filings
  • SHAAN C. GANDHI, MD, DPhilDirectorNamed in SEC Form D filings
  • TERESA C. McROBERTSExecutive OfficerNamed in SEC Form D filings
  • WIDYA M. MULYASASMITADirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • TREVENA INCSimilar federal contract value in Biotech · null in contracts
  • LifeCyte Innovations, Inc.Similar federal contract value in Biotech · null in contracts
  • Revalesio CorpSimilar federal contract value in Biotech · null in contracts
  • MEISSA VACCINES INCSimilar federal contract value in Biotech · null in contracts
  • DRUG DESIGN METHODOLOGIES, L.L.C.Similar federal contract value in Biotech · null in contracts
  • AdvanCellSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .